Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial

(2019) David W Dodick et al.   CEPHALALGIA

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

(2018) Vladimir Skljarevski et al.   CEPHALALGIA

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine

(2018) David W. Dodick et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy

(2018) Bianca Raffaelli et al.   Neurotherapeutics

Migraine and risk of cardiovascular diseases: Danish population based matched cohort study

(2018) Kasper Adelborg et al.   BMJ-British Medical Journal

Migraine and risk of cardiovascular diseases: Danish population based matched cohort study

(2018) Kasper Adelborg et al.   BMJ-British Medical Journal

Evaluation of Galcanezumab for the Prevention of Episodic Migraine

(2018) Virginia L. Stauffer et al.   JAMA Neurology

The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis

(2018) Yuhan Zhu et al.   NEUROLOGICAL SCIENCES

A phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the arise trial

(2017) David Dodick et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Fremanezumab for the Preventive Treatment of Chronic Migraine

(2017) Stephen D. Silberstein et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Controlled Trial of Erenumab for Episodic Migraine

(2017) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Migraine and its psychiatric comorbidities

(2016) Mia Tova Minen et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Migraine and risk of cardiovascular disease in women: prospective cohort study

(2016) Tobias Kurth et al.   BMJ-British Medical Journal

Migraine and risk of cardiovascular disease in women: prospective cohort study

(2016) Tobias Kurth et al.   BMJ-British Medical Journal

Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations

(2014) G. Shankar et al.   AAPS Journal

The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results

(2014) Aubrey Manack Adams et al.   CEPHALALGIA

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

(2014) David W Dodick et al.   LANCET NEUROLOGY

Placebo Effects: From the Neurobiological Paradigm to Translational Implications

(2014) Fabrizio Benedetti   NEURON

Altered Placebo and Drug Labeling Changes the Outcome of Episodic Migraine Attacks

(2014) S. Kam-Hansen et al.   Science Translational Medicine

Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura

(2010) Jakob Møller Hansen et al.   CEPHALALGIA

CGRP and its receptors provide new insights into migraine pathophysiology

(2010) Tony W. Ho et al.   Nature Reviews Neurology

Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment

(2008) M. E. Bigal et al.   NEUROLOGY